Multivalent anti-SARS-CoV-2 nanobodies
US12098186B1 · kind B1 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2022 |
| Grant date | Sep 24, 2024 |
| Priority date | — |
| Expiry date | Jul 16, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are asymmetric biparatopic neutralizing nanobody-based antibodies which engage SARS-2 spike in at least two independent epitopes. Several biparatopic constructs showed synergy in neutralizing viral infection of cells. Data also showed that single biparatopic constructs are more effective than the combination of the parental monotopic constructs were at neutralization. The nanobodies that were identified in an initial screen of a large and highly diverse library bind to a single epitope that overlaps with the ACE2 binding site.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.